FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3214715896> ?p ?o ?g. }

• W3214715896 endingPage "2755" @default.
• W3214715896 startingPage "2755" @default.
• W3214715896 abstract "Abstract Background: RO7297089 is a bispecific tetravalent antibody targeting BCMA (Genentech licensed from Affimed GMBH), which is highly expressed on MM cells and CD16a, which is expressed on innate immune cells including natural killer (NK) cells, macrophages, and monocyte subsets. Here we report findings from a Phase I dose-escalation study of RO7297089 in patients with RRMM (GO41582, Study registration NCT04434469). Methods: All patients had RRMM for which no established therapy is available, appropriate, or tolerated. Prior exposure to CAR-T cells, T-cell engaging bispecific antibodies, and therapies targeting BCMA was permitted. Patients received RO7297089 as weekly IV infusions in 14-day cycles with dose escalation guided by a model implementing the Bayesian continuous reassessment method with overdose control. In Arm A the first dose was given over a single-day infusion, and in Arm B the first dose was divided over two consecutive days. Dose limiting toxicities (DLT) were assessed from Cycle 1. Study objectives included safety, pharmacokinetics (PK), and biologic activity as assessed by the IMWG Uniform Response Criteria. Results: As of 30 April 2021, 21 patients received RO7297089 at 5 dose levels (60 mg [n=3], 180 mg [n=5], 360 mg [n=4], 1080 mg [n=6], and 1850 mg [n=3]). Median age was 63 years (range 41-76) and median number of prior lines of therapy was 8 (range 2-11). Patients received a median of 8 doses (range 2-42) of RO7297089; 5 patients had prior BCMA-targeted therapy. The most common AEs were anemia (n=11), infusion related reaction (IRR; n=10), back pain (n=5), ALT increased (n=4), and thrombocytopenia (n=4). Eleven (52%) patients had ≥1 treatment-related adverse event (AE) which included IRR (n=9), C-reactive protein increase (n=3), ALT increase (n=3), AST increase (n=2), and thrombocytopenia (n=2). Grade ≥ 3 AEs included anemia (n=9), and platelet count decreased (n=5). Related Grade ≥ 3 AEs were ALT increase and AST increase and lymphocyte count decreased (both n=1). No DLTs or dose-dependent toxicities were reported. Fifteen patients discontinued study treatment due to disease progression (n=12), clinical relapse (n=2), and symptomatic deterioration (n=1). Four deaths were reported in the AE follow-up period, all due to disease progression. Thirteen IRR events (1 Grade 1, 12 Grade 2) were observed in 10 patients (48%). IRR was most common in Cycle 1 (12 events in 10 patients) and was uncommon in subsequent cycles (1 patient). Symptoms of IRR occurring in &gt;1 patient included fever, rigors/chills, and dyspnea. To mitigate IRRs, additional measures were implemented from the 180 mg dose level including steroid premedication and slow infusion for the first dose. Dividing the first dose over 2 days (Arm B) was also implemented from the 1080 mg dose level for improved convenience. Preliminary PK assessments demonstrated a more than dose proportional increase in the exposure of RO7297089 with increasing dose levels from 60-1080 mg, suggesting non-linear PK and target-mediated drug disposition, with a trend of approaching linear PK at doses higher than 1080 mg. The estimated half-life was supportive of weekly dosing. Preliminary observation showed 1/18 patients with treatment-induced anti-drug antibodies, which did not appear to impact PK. BCMA expression was detected in the bone marrow in all patients regardless of prior BCMA-targeted therapy. Levels of total soluble BCMA and soluble CD16a increased immediately after the first dose as expected suggesting engagement and stabilization of soluble factors by RO7297089. Of the 18 response-evaluable patients, 1 patient experienced a partial response (1080 mg cohort) per IMWG criteria. Ten patients had stable disease as their best response at dose levels of 60 mg (1/3 patients), 180 mg (2/5 patients), 360 mg (3/4 patients), 1080 mg (4/6 patients). One patient who started at the 60 mg dose and gradually escalated to the 1080 mg dose has been on treatment for 9.5 months with stable disease at the time of the clinical cut-off date. Conclusions: Treatment with RO7297089 was well-tolerated at the dose levels tested, although infusion reactions necessitated long infusion duration for the first dose. Modest activity has been observed to date with doses up to 1080 mg. There were no DLTs and a recommended phase 2 dose has not been identified. The latest clinical, biomarker, and PK data will be presented including data from higher dose level cohorts. Disclosures Plesner: AbbVie: Other: Advisor, Research Funding; CSL Behring: Other: Advisor; Genentech: Other: Advisor, Research Funding; Oncopeptides: Other: Advisor, Research Funding; Takeda: Research Funding; Celgene: Other: Advisor, Research Funding; Genmab: Research Funding; Janssen: Other: Advisor, Research Funding. Harrison: Celgene/ Juno/ BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Janssen Cilag: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Roche/Genentech: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Abbvie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Terumo BCT: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Haemalogix: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Eusa: Consultancy, Honoraria, Speakers Bureau. Quach: GlaxoSmithKline: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol Myers Squibb: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen/Cilag: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Antengene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; CSL: Consultancy, Membership on an entity's Board of Directors or advisory committees. Lee: BMS: Other: Advisor, Research Funding; Janssen: Other: Advisor; Amgen: Other: Advisor. Bryant: Sandoz: Honoraria; Amgen: Honoraria; Pfizer: Honoraria; Roche: Honoraria. Estell: Celgene: Membership on an entity's Board of Directors or advisory committees; Janssen-Cilag: Membership on an entity's Board of Directors or advisory committees. Delforge: Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees. Twomey: Genentech: Current Employment. Choeurng: Genentech: Current Employment. Li: Genentech: Current Employment. Hendricks: Genentech: Current Employment. Sumiyoshi: Genentech: Current Employment, Current equity holder in publicly-traded company, Divested equity in a private or publicly-traded company in the past 24 months. Miller: Genentech: Current Employment. Choi: Genentech: Current Employment. Schjesvold: Schain: Honoraria; AbbVie: Honoraria; Adaptive Biotechnologies: Consultancy; Nordics Nanovector: Current holder of individual stocks in a privately-held company; Sanofi: Consultancy, Honoraria, Research Funding; Oncopeptides: Consultancy, Current holder of individual stocks in a privately-held company, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; GSK: Research Funding; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; SkyliteDX: Honoraria; Bayer: Consultancy; Celgene/BMS: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria. OffLabel Disclosure: RO7297089 is a Bâ€'Cell maturation antigen (BCMA)-CD16a bispecific antibody intended for use if approved in patients with relapsed/refractory multiple myeloma" @default.
• W3214715896 created "2021-11-22" @default.
• W3214715896 creator A5006799794 @default.
• W3214715896 creator A5009555081 @default.
• W3214715896 creator A5015912578 @default.
• W3214715896 creator A5028513168 @default.
• W3214715896 creator A5028707750 @default.
• W3214715896 creator A5029295767 @default.
• W3214715896 creator A5048676830 @default.
• W3214715896 creator A5054416214 @default.
• W3214715896 creator A5064831033 @default.
• W3214715896 creator A5070696114 @default.
• W3214715896 creator A5071712855 @default.
• W3214715896 creator A5074821198 @default.
• W3214715896 creator A5078740906 @default.
• W3214715896 creator A5088496212 @default.
• W3214715896 creator A5089925113 @default.
• W3214715896 creator A5091396091 @default.
• W3214715896 creator A5039283738 @default.
• W3214715896 date "2021-11-05" @default.
• W3214715896 modified "2023-10-14" @default.
• W3214715896 title "A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)" @default.
• W3214715896 doi "https://doi.org/10.1182/blood-2021-147418" @default.
• W3214715896 hasPublicationYear "2021" @default.
• W3214715896 type Work @default.
• W3214715896 sameAs 3214715896 @default.
• W3214715896 citedByCount "10" @default.
• W3214715896 countsByYear W32147158962022 @default.
• W3214715896 countsByYear W32147158962023 @default.
• W3214715896 crossrefType "journal-article" @default.
• W3214715896 hasAuthorship W3214715896A5006799794 @default.
• W3214715896 hasAuthorship W3214715896A5009555081 @default.
• W3214715896 hasAuthorship W3214715896A5015912578 @default.
• W3214715896 hasAuthorship W3214715896A5028513168 @default.
• W3214715896 hasAuthorship W3214715896A5028707750 @default.
• W3214715896 hasAuthorship W3214715896A5029295767 @default.
• W3214715896 hasAuthorship W3214715896A5039283738 @default.
• W3214715896 hasAuthorship W3214715896A5048676830 @default.
• W3214715896 hasAuthorship W3214715896A5054416214 @default.
• W3214715896 hasAuthorship W3214715896A5064831033 @default.
• W3214715896 hasAuthorship W3214715896A5070696114 @default.
• W3214715896 hasAuthorship W3214715896A5071712855 @default.
• W3214715896 hasAuthorship W3214715896A5074821198 @default.
• W3214715896 hasAuthorship W3214715896A5078740906 @default.
• W3214715896 hasAuthorship W3214715896A5088496212 @default.
• W3214715896 hasAuthorship W3214715896A5089925113 @default.
• W3214715896 hasAuthorship W3214715896A5091396091 @default.
• W3214715896 hasBestOaLocation W32147158961 @default.
• W3214715896 hasConcept C126322002 @default.
• W3214715896 hasConcept C142424586 @default.
• W3214715896 hasConcept C143998085 @default.
• W3214715896 hasConcept C159654299 @default.
• W3214715896 hasConcept C203014093 @default.
• W3214715896 hasConcept C2776364478 @default.
• W3214715896 hasConcept C502942594 @default.
• W3214715896 hasConcept C71924100 @default.
• W3214715896 hasConcept C86803240 @default.
• W3214715896 hasConcept C87355193 @default.
• W3214715896 hasConceptScore W3214715896C126322002 @default.
• W3214715896 hasConceptScore W3214715896C142424586 @default.
• W3214715896 hasConceptScore W3214715896C143998085 @default.
• W3214715896 hasConceptScore W3214715896C159654299 @default.
• W3214715896 hasConceptScore W3214715896C203014093 @default.
• W3214715896 hasConceptScore W3214715896C2776364478 @default.
• W3214715896 hasConceptScore W3214715896C502942594 @default.
• W3214715896 hasConceptScore W3214715896C71924100 @default.
• W3214715896 hasConceptScore W3214715896C86803240 @default.
• W3214715896 hasConceptScore W3214715896C87355193 @default.
• W3214715896 hasIssue "Supplement 1" @default.
• W3214715896 hasLocation W32147158961 @default.
• W3214715896 hasOpenAccess W3214715896 @default.
• W3214715896 hasPrimaryLocation W32147158961 @default.
• W3214715896 hasRelatedWork W2047345996 @default.
• W3214715896 hasRelatedWork W2351796763 @default.
• W3214715896 hasRelatedWork W2351985199 @default.
• W3214715896 hasRelatedWork W2403502999 @default.
• W3214715896 hasRelatedWork W2435227317 @default.
• W3214715896 hasRelatedWork W2567738959 @default.
• W3214715896 hasRelatedWork W2699314556 @default.
• W3214715896 hasRelatedWork W2923882796 @default.
• W3214715896 hasRelatedWork W2954318774 @default.
• W3214715896 hasRelatedWork W4297834875 @default.
• W3214715896 hasVolume "138" @default.
• W3214715896 isParatext "false" @default.
• W3214715896 isRetracted "false" @default.
• W3214715896 magId "3214715896" @default.
• W3214715896 workType "article" @default.